<SEC-DOCUMENT>0001188112-11-003098.txt : 20111107
<SEC-HEADER>0001188112-11-003098.hdr.sgml : 20111107
<ACCEPTANCE-DATETIME>20111107170156
ACCESSION NUMBER:		0001188112-11-003098
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20111101
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20111107
DATE AS OF CHANGE:		20111107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	INDUSTRIAL ORGANIC CHEMICALS [2860]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	002-90539
		FILM NUMBER:		111185327

	BUSINESS ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631 444 6861

	MAIL ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t71894_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head>
    <title>t71894_8k.htm</title>
    <!--Licensed to: ga4252-->
    <!--Document Created using EDGARizerAgent 5.4.2.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WASHINGTON, D.C. 20549</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="13%">
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">FORM 8-K</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CURRENT REPORT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="13%">
</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date of report (Date of earliest event reported): November 1, 2011</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Applied DNA Sciences, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact Name of Registrant as Specified in Charter)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Delaware</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State or Other Jurisdiction</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of Incorporation)</font></div>
</td>
<td valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">002-90539</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Commission File Number)</font></div>
</td>
<td valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">59-2262718</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(IRS Employer</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25 Health Sciences Drive, Suite 215</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stony Brook, New York 11790</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address of Principal Executive Offices) (Zip Code)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">631-444- 8090</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant&#8217;s telephone number, including area code)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not Applicable</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former Name or Former Address, if Changed Since Last Report)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="3" valign="top" width="100%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#160;</font></td>
<td valign="top" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
</td>
<td colspan="2" valign="top" width="97%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#160;</font></td>
<td colspan="2" valign="top" width="97%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
</td>
<td colspan="2" valign="top" width="97%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#160;</font></td>
<td colspan="2" valign="top" width="97%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
</td>
<td colspan="2" valign="top" width="97%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">240.14d-2(b))</font></td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#160;</font></td>
<td colspan="2" valign="top" width="97%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
</td>
<td colspan="2" valign="top" width="97%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: gainsboro" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="80%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1.01&#160;&#160;Entry into a Material Definitive Agreement</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Nissha Sales Agreement</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On November 1, 2011, we entered into an Exclusive Sales Agreement (the &#8220;Agreement&#8221;) with Nissha Printing Co., Ltd. (&#8220;Nissha&#8221;), pursuant to which we granted Nissha an exclusive right to sell their printing inks and related products incorporating our SigNature DNA authentication markers, initially for fish and fruit products, publications and wood applications, in various countries in Asia for an initial period of three years.&#160;&#160;The exclusivity rights granted to Nissha are conditioned upon Nissha achieving minimum sales targets (or, if below the specified thresholds, paying the shortfall) and payment of annual fees.&#160;&#160;We also granted Nissha the non-exclusive right to sell their printing inks and related products incorporating our SigNature DNA authentication markers for cosmetics products in the same geographic area during the term of the agreement.&#160;&#160;We have agreed to supply our SigNature DNA authentication markers to Nissha on pricing terms and conditions to be set forth in the applicable purchase orders.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The foregoing description of the Agreement is a summary and does not purport to be complete and is qualified in its entirety by reference to the copy of the Agreement, which will be filed as an exhibit to our Form 10-K for the year ended September 30, 2011.&#160;&#160;A copy of our press release announcing the Agreement is attached hereto as Exhibit 99.1.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="80%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 9.01. Financial Statements and Exhibits.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="100%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(d)&#160;&#160;Exhibits.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="95%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
</td>
<td align="left" valign="top" width="95%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press release issued by Applied DNA Sciences, Inc. on November 7 2011, filed herewith.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: gainsboro" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Applied DNA Sciences, Inc.</font></font></font></div>
</td>
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></font></div>
</td>
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="27%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="23%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="27%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="23%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="27%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="23%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></td>
<td valign="top" width="24%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ James A. Hayward</font></td>
<td valign="top" width="23%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="27%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James A. Hayward</font></font></font></td>
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%">&#160;</td>
<td colspan="2" valign="top" width="27%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></font></font></td>
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="24%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="24%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="24%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: November 7, 2011</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="24%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: gainsboro" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT INDEX</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Applied DNA Sciences, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 8-K Current Report</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit Number</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Description of Document</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press release issued by Applied DNA Sciences, Inc. on November 7, 2011.</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>ex99-1.htm</title>
    <!--Licensed to: ga4252-->
    <!--Document Created using EDGARizerAgent 5.4.2.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right">EXHIBIT 99.1</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="81%" style="BORDER-RIGHT: black; BORDER-TOP: black; BORDER-LEFT: black">&#160;</td>
</tr><tr>
<td valign="bottom" width="81%" style="BORDER-RIGHT: black; BORDER-LEFT: black; BORDER-BOTTOM: black">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg" alt="graphic"></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="1%" style="BORDER-TOP: steelblue 2px solid; BORDER-LEFT: steelblue 2px solid; BORDER-BOTTOM: steelblue 2px solid; TEXT-ALIGN: left"><font color="black" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="22%" style="BORDER-TOP: steelblue 2px solid; BORDER-BOTTOM: steelblue 2px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font color="black" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font color="steelblue" style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PRESS RELEASE</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 7, 2011</font></font></div>

<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="76%" style="BORDER-TOP: steelblue 2px solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: steelblue 2px solid; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For Immediate Release</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contact:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Media Relations</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1-631-444-6370</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Applied DNA Sciences</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</td>
<td valign="top" width="1%" style="BORDER-RIGHT: steelblue 2px solid; BORDER-TOP: steelblue 2px solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: steelblue 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="1%" style="BORDER-TOP: medium none; BORDER-LEFT: steelblue 2px solid; BORDER-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="middle" width="80%" style="BORDER-TOP: medium none; BORDER-BOTTOM: 4px; TEXT-ALIGN: left">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: times new roman">Secure DNA Printing for Food</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman">Nissha Printing Co., Ltd. Inks Exclusive Agreement with Applied DNA Sciences</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman">DNA will ensure food safety and identity</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="3">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="3">&#160;</font></div>
</div>
</td>
<td valign="middle" width="1%" style="BORDER-RIGHT: steelblue 2px solid; BORDER-TOP: medium none; BORDER-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="middle" width="1%" style="BORDER-LEFT: steelblue 2px solid; BORDER-BOTTOM: steelblue 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="middle" width="80%" style="BORDER-BOTTOM: steelblue 2px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">STONY BROOK, N.Y., November 7, 2011/Marketwire/ - Applied DNA Sciences, Inc. (OTCBB:APDN), Twitter:@APDN), www.adnas.com.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nissha Printing Co., Ltd. (Nissha), an innovative printer and a half-billion-dollar company based in Japan, will use APDN technology in a remarkable project to protect the brands of highly valued fish and other products, recently victims of rampant counterfeiting. The new printing system uses "DNA ink," derived from plant DNA, to mark and authenticate labels on high-value fish and other food products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The company signed an exclusive agreement with APDN on October 31, becoming the sole provider of DNA ink products in publications and foods (fish and fruit) in Asia. APDN is already recognizing sales revenue from its relationship with NISSHA and is looking forward to a stronger presence in Asia. This agreement compliments the already existing agreement between Nissha and APDN and further strengthens the relationship between the two companies.&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Please also refer to our SEC Form 8K. &#160;The filing will be available by the end of the business day, on November 7.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Authenticating Food</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Using the new printing system, foods can be instantly verified as genuine in the field, using a special handheld detector to identify the anti-counterfeiting ink. This could happen at the point of sale, or at any point along the supply chain. As is typical of APDN DNA markers, a second, forensic level of authentication is also available by sending the suspect product to a secure lab.&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The system is entirely safe and non-invasive; foods are not altered.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Branded foods from particular and often well-known waters off Japan, and sometimes preserved with traditional, labor-intensive methods, are becoming popular, profitable, and necessary in Asia. For example, sushi bars have become ever more discriminating, while ocean contamination and other issues beset the fishing industry.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Counterfeiters and diverters have moved in with force, selling common foods as the high-value brand, destroying markets and reputation of the real item.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</td>
<td valign="middle" width="1%" style="BORDER-RIGHT: steelblue 2px solid; BORDER-BOTTOM: steelblue 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: gainsboro" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="1%" style="BORDER-TOP: steelblue 2px solid; MARGIN-LEFT: 0pt; BORDER-LEFT: steelblue 2px solid; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: steelblue 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="middle" width="80%" style="BORDER-TOP: steelblue 2px solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: steelblue 2px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">APDN's ironclad anti-counterfeiting</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nissha identified APDN's technology as the most ironclad product authentication solution, stating its determination that DNA, as a trusted forensic form of authentication in courts around the world, provides the highest security for high value food and other products.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">And Nissha views DNA protection of food as just the beginning. "No product is safe from the threat of counterfeiting, and this threatens public health and safety, especially in relation to food and other consumer products," commented Takao Hashimoto, Director and Chief Technology Officer of Nissha.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The new system, developed by Nissha in conjunction with APDN, can also package a wide variety of products with its forgery-proof, high security layer. The anti-counterfeiting DNA ink on labels can be delivered by various printing technologies, such as offset printing, gravure printing, and ink jet printing.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nissha, listed on the Tokyo Stock Exchange (Company Code: 7915), has a market capitalization of 40 billion JPY (or approximately $500 million US dollars). Headquartered in Kyoto, Japan, Nissha is a globally networked company with over 4,000 employees (consolidated), 11 locations in Japan and 27 bases located throughout Asia, North America and Europe.</font></font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">APDN's ironclad anti-counterfeiting</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nissha identified APDN's technology as the most ironclad product authentication solution, stating its determination that DNA, as a trusted forensic form of authentication in courts around the world, provides the highest security for high value food and other products.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">And Nissha views DNA protection of food as just the beginning. "No product is safe from the threat of counterfeiting, and this threatens public health and safety, especially in relation to food and other consumer products," commented Takao Hashimoto, Director and Chief Technology Officer of Nissha.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The new system, developed by Nissha in conjunction with APDN, can also package a wide variety of products with its forgery-proof, high security layer. The anti-counterfeiting DNA ink on labels can be delivered by various printing technologies, such as offset printing, gravure printing, and ink jet printing.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nissha, listed on the Tokyo Stock Exchange (Company Code: 7915), has a market capitalization of 40 billion JPY (or approximately $500 million US dollars). Headquartered in Kyoto, Japan, Nissha is a globally networked company with over 4,000 employees (consolidated), 11 locations in Japan and 27 bases located throughout Asia, North America and Europe.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ABOUT APDN</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">APDN sells patent-protected DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. APDN's botanical markers are used to authenticate products in a unique manner that essentially cannot be copied, and provide a forensic chain of evidence that can be used to prosecute perpetrators. To learn more, go to www.adnas.com where </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">APDN routinely posts all press releases.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10k/a filed July 24, 2011, and our subsequent quarterly reports on Form 10-Q. APDN </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">INVESTOR CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">MEDIA CONTACT: Mitchell Miller, fax: 631-444-8848; mitchell.miller@adnas.com</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FCMN Contact: info@adnas.com</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Web site: http://www.adnas.com</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Twitter: @APDN, @APDNInvestor</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="middle" width="1%" style="BORDER-RIGHT: steelblue 2px solid; BORDER-TOP: steelblue 2px solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: steelblue 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></td>
</tr></table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!&`;`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BN5G^.O@BV^(Z^#I?&7A6/Q<Q"C0VU:W&I$F/S0/LY?S,
MF,AQ\OW>>G-=50`4444`%%%%`!163XW\?:%\,_#DVL>)-:TGP_I%L566^U*\
MCM+:(LP50TDA"@EB`,GDD"G>#/'&B_$?PU;:UX=UC2]>T>]W?9[[3KJ.ZMI]
MKE&V21DJV'5E.#P5(Z@T`:E%%8>M?$_PUX;\36FB:CXAT2PUF_"&VL;B^BBN
M;C>Q5=D;,&;+*0,#DC'6JC"4G:*N3*26[L;E%%%24%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!16;XQ\9:1\//"FI:]K^J:?HFA
MZ/;/>7^H7]PEO:V4"*6>621R%1%4$EF(``K\,O\`@J+_`,'B&E:/!J_@[]EK
M2CJ]U+"L<?Q!UFU>&VMV906:TT^>,/(R[BH>Y"*'0_N9$PS`'[:_&;XY>#/V
M=/A]?>+/'OBG0/!WAG30OVG4]8OH[.UB+,%52[D#<S,JJHY9F``)(%?E#^V?
M_P`'DWP.^#.IVVG_``;\(:]\:IFPUQJ,\TOAK3(E*$XC-Q;O<R2*V`RM;QK@
MY$C=*_G>_:=_:R^)/[9WQ2N?&GQ2\9:WXU\2W2^7]KU"8%8(\DB*&)0(X(@2
M2(XE5`6)`&37U!_P2@_8K_9&_:8U?1Y/V@/VG)OAEJ-U>SP2>%$T*6R$\2QL
M8Y6UR8/96X+#)62/)`VA@S`@`VOVJ?\`@YL_;"_:C_M:S3XE?\*XT#5?)_XE
M?@FR326M/+*L#%>_/?H6906Q<X;++C82M?5?_!II^RU^T_HW[<!^)Z:=XP\,
M?!'6]+N9O%E[K<<MO9>-#)%<"S%L)ES=31W9\WSX_P#5HLRM*OG^7+^UG[#W
M_!*;]F/]BCR/$?P9^&?A/3+Z]3SK;Q")Y=8OBC1LA,%[<R321HZ,P*Q.J,&Y
M!KZ8H`****`"BBB@`HHHH`****`"BOQO_P""X'_!<SXS>$/VQ+;]DK]DW0+V
M_P#BU<>7;:SJD6DI?WL,TUO!>11:>K,T2A+9I&GFGC*QH6(,?E-(/F'XH_#W
M_@JQ_P`$C?"P^./B'XEZA\3/#&F#[7XATJY\1S^)[/38/XOM5I,$*1#<=TEH
MV$`R711F@#^BZBOF/_@DK_P4JT+_`(*D?L3Z+\5;"TM]#U..:72O$>E"8R+H
M^H0!3+'O(&4:-XYD//[N9`3N#`?D)\0O^"LO[9O_``7H_:?\2?#S]CXZA\-?
MA9X><-+K<9_LN\BMW4"*;4M0!D:!Y)(9C%#:;7*%U(E$;NH!_0O17\[5E_P4
M0_;N_P"#>SX[^&M*_:<N=0^,?PD\3SB,W]QJ3:P\R`[I6L=0DVS)<H&SY%U\
MKJN`%!$J_KQ_P4@_X*O^"/V#_P#@G;)\?;":R\7V/B&UL_\`A"[:*X\J/Q)<
M7L?F6NUB,B/R=\[\;A%$^!NP*`/JVBOYT_ACX(_X*L?\%?/")^-OA[XD7OPP
M\+:@3=^'M)M/$%QX6L]2AP,?9;:$,\L/RC;)=N0X.0[*2:^E_P#@B!_P7,^,
M_B7]L:?]DG]K/0;RQ^*T`DM=&U6;3$L;Z2>&WFO)(=0"L(G#VRQM!-#&%D4*
M29#*LA`/G?XM_P#*[M:?]AK2O_40MJ^U_P#@MM\;OV]_AS^V[\&M*_9;\+WN
MK>`+^T22^DM]&BOK"^U+[4RS6^JSOG[):+`+?:VZ#(FG*RED'E?%'Q;_`.5W
M:T_[#6E?^HA;5Z]_P<K_`+??QG_98_X*4_`7PK\.OB3XI\'>'/$6DV<VIZ?I
MEV88+UWU66)F<=R8P%^@H`_;^BOSQ_X."O\`@MO)_P`$C/@[X<T[PCI%AKWQ
M4^()G;14U!1+IVDVUO)`)[FYC25)6+"79"HPK.KLS$1&-_SET7]C_P#X+`^+
M_AROQP'Q0\966MRP_P!IQ^#+GQ*+74GCV\#^R#&+%&*?-]G?;)GY3&)/EH`_
MHHHK\W_^#?/_`(+?7_\`P5,\"^+/!_Q(TK3?#?QC^&P234XK?%M!K=F\CQ_:
MHK=W,L4D+JL=PN"BO+"P*^;Y4?PA\:?^"NG[8'_!<K]J[Q%\+_V,'U/P1\*]
M"E`D\26\#:5>&!D&VXU#4"7:U$DL,Y@BM_+E="P99"C;`#]`/^#J/_E"+\5?
M^OW0_P#T[V=:G_!KY_R@O^!W_<>_]2#4J_%__@J]J/[?O[!_[)>L?!7]H[7?
M^%C_``K^)=W:+9>*KJ\DUP6]U:SI>"&&^;9/'(YC&8[M3O2-S$/D=A^I?_!$
MS]JO2?V-?^#:_P"$OC;5(5OIK8ZW:Z=IXN$ADU*[D\0ZD(XE+=@-SL5#,L<<
MC!6VX.^%PU7$5HT*,>:4FDEW;T1E7KPHTY5:CLHJ[/U0//<BORY_X*>_\IF?
M@-_W+7_I\N*YWP):_MH?\%#]/;X@Z/XKF\%^&R3)IL5OJDVBV%V`=K+#%'OD
MF4,GWIR5R2%8\@>-7_Q0^)GQ)_X*4?"*V^+MM]F\<^$_$>@Z'>!X$AFD1=26
M='D$9\MF*W'#1@*R;"`<EF_4.&^%YX/$5:OMZ<Y0I5>>,97E&\&NUGJ[.S=C
MXG-\[6)HTX>RG%2G%IM63U_5:G[FT5\2?\%>_P#@HCXA_93L_#W@KX?RVJ>-
MO%$;7,UPT'VB?3K7=Y<1BC(*M++*&"E@P`B<;264CY:\>W_[9?\`P3\TW2?B
M1XF\3:QKFC7TB?VA97VK2ZQ96#OG;#=19VPAF8J&@8)NVC>"4!^8RO@W$XW#
MTZSJPINJVJ<9.TIM::*VU]+OK\CW<;Q!1P]65/DE)0MS-*ZC?NS]@**\)T#]
MOWP?=_L-P_'C4(=3L_#9M#--9I$);I9Q<FT^SH.`Q-P/+5B54@AF*KDCX/\`
M"WCO]K__`(*AW]_X@\(ZO/\`#WP="Q6R:UO9]'L6PY!6*XC4SW#J8\.P)4-D
M83.VN3+>&,1B?:SKSC1A3?+*4W9*7\JM=M^2_57UQN=T:/)&G%U)35THJ[MW
M]#]9J*_,K]EC_@HE\7_V6/VF],^#O[0\;3V^I3QVL&L7[*+BU$N5@G$Z#9<0
M/)A"[$%,L6<&-D'E_P#P<P?\%9?BM^SE\9?AA^S9\$]>M?!'BWXGVD5]JWB:
MYD2R:P@N;[[)9I!>O($M5,D%T9Y73*)Y161?GKBSG):^758PJM2C)7C*+O&2
M[I_H=&79E3QD'*":<79IZ-,_86BOR0_X)<?\$R?^"@7[(7[:O@OQ'\7/VC;?
MXI?"6;[9%XDTEO&VJZY(5;3[D6SK'J%NH`6[-N<Q.&..05S6U_P7\_X+X>)/
MV!OB%X;^!_P)TC3?%?QM\5I$]R6MVU)M"6X;R[2WCM(SF6^G8ADC?.U/+)CD
M$R8\<]$_56OR_P#AA\9OVZK[_@X5USPCXDT?5X_V68A>>5<VN@Q+H,5@-,=[
M*6._DA622\:[,`E02.0[S*%\I%*^9_\`!+#]FK_@IJ?VS_A_X^_:&\>WR_#)
M7NI]?\/76O6?F2))8SI`#:6B^4"L[0MM!!4J21D$5F_\-T?&#_B+^_X4I_PL
M/Q/_`,*G_P"A6^U'^S?^1*^V_P"K_P"OG][_`+W-`'[/45^/G_!=O_@N5\5_
MA3^T_8_LI_LJ:+?:O\9=0BC37+^#13?WNFO/##=P0:>C$QM+]E+R32R1/'%%
M("I#J[1?*OQ1^$G_``5@_P""6'@23XZZS\3M5^(F@Z.IU#Q'HLGB.7Q/!I=L
M/]8US9S*%6$!CO>S8^4JLY:-4W@`_HMHKXU_X)U_\%D/!?[:_P#P3)U;]H;5
MH!H`\`:=?S>.=+M`]PVD7%A;FXN!$&P9$D@V2QC)XE"%BZMC\@OA;^TG_P`%
M'/\`@X4\<^,/&'P@\9S_``B^'_@ZX^SVUKI&N7/A_3(YF3<MDMU$IGO;KR]C
MR%SY:&16Q`LL:$`_I'HK\:/^#?G_`(+8_%KXD_M5>(?V4/VHC*?BEH8N;;0M
M0N+)8K^YNK/SY+VSO'C;RY'6%0\4B(%9+>0L[ED+6?\`@N)_P7D^,'PL_:\B
M_97_`&4_#=UJ_P`6&C2+6=131#JE[!/-;0WD,6G19:-F2V9WFDFB=$5C@*8V
M<`'['45^0W_!*;]D3_@I+X(_;9\%^,/VBOB9+J7PQMHKXZYH4OB:&[>1I+&=
M+=?(@0Q,5N'B;Y7P-F<G`!^>/VL/^"QW[5/_``6'_;0U[X(?L1R7V@_#[0+A
MX9?%FG)]CN=0C0$/>W-^Q86=H\D;^0(_+EE4C=N9_)0`_H`HK^=#QI^UK_P4
M4_X-Y?'_`(<UCXWZY/\`&[X4^(KH6T\U_J\^MV,T@P[P)J$J"YL[HQ[S&)1Y
M;[7(241.%^S/^"\O_!?&Z_9>_8!^$7BKX"7ZR:S^T3;37^@^(GMX9TT73K>*
MW>Y/EN65;T/=P1!'1Q&5GW`.B@@'ZQT5^#?P(_X)<?\`!4/P!=^&?B;I?[5=
MEX[LKA[74I]$3XCZCK*7]M(Z&2.)+R`Z>Y\MFY$@3Y?D<_*3^W_QG\$WOQ+^
M#WBSPWINK7.@ZCX@T:\TVUU.W8K-ITLT#QI.A'(9&8,".ZB@#^5K_@X*_P""
MY>M?\%._C9>>"_!.IW=E\"/"-\RZ-!&DUI+XFE"1*U[>1F1ED42I(;<,B,D4
M@+*LC,!RG_!,G]@#X1ZAKZ>*/VF+?XC3Z#%Y4UAX7\+Q00SWQ$C>8M]--+&\
M,955`2#]XPD)\V(IAOD[X:W$W[*'[6/AJZ^(7@>749/AYXJL[KQ#X1UNV^SM
M>K:72/<:?<1RHVT2*C1L'0C#'*GH?W_^"G_!8WX'?M%>'VU+P9^QY\,M=AB"
MF>*WALWGLR2P"S(NG$QDE6QG@XR"1@GZ;AC+:.,KRIU:4JMEHHSA!^MY;^B/
M%SK&5*$(NG-0N]W&4OEHM/G\CP/]KG]E#_@G9^TGJ#ZEX<\`?'3X1ZPT+*!X
M5735T^>3`"O):W%S*H"X^[`8=V3DY.:_,WXY_P#!-?7/!6O:A)X'U=O&?A^%
M_P#0Y+RT32]3N$VY+-;"6:)2#QA9W)X]<#]XA_P4)\`B6-'_`&&_`R&3H/L%
MON([X!TSFF)_P4.\`2;-O[#O@-O,SLQ96QW8ZX_XEG.*^RGPA1E%\F`J*^S]
MO2?Z:]?ZW^?CGE>,ES8F/I[.?EY>:^\_GO\`@-^TQ\=/^"=WCQ=9\!^*/'/P
MPU:=EEE2%Y+:WU`)O5?/MY!Y-PJ[GP)$=022!FOU$_8]_P"#S_XK>"M7L-/^
M-O@#POXXT&.-(9]4\/1OI>L9`.Z9XV=K:9CQ\B+`O7D<8^P-9_;M^%_BO3Q:
M:E^P?\.-2LY\GR;C2[2>.3'^RVF$'%?$/[:G[$7P*_:>O[O6O"G[./C?X+^(
M+M6V#PUK[MI$DQQAGL9M/8``#`CMW@!R3R>OS=?@3-N>U*CIVE.G?3?[?XZ?
M@>S1XDP;A>I/7RC.WE]D_2;X1?\`!V3^S'\9@8M-TGXG6-^76-+'4+#3K>XD
M+9P%'VTJ^<'[C,1QG&1GT@?\'"_P=)`'A3XFDGI_H5A_\EU_,1\5?^"9GQ=^
M&@^U6/A76_$E@"?WVEZ=<32QX&26C";@/==P&1DC->K_`/!-W_@M-KG[#^IQ
MZ1XV^&?PX^-W@:6;,]GXGT6WEUBS7:X_T2_>-G7YF0E)EF3;'M01Y+#BIPP&
M#D\/FN&GSKM.WX.+^].WD:SEBL2O;8"O'E?>-[?._P"#5S^B%?\`@X6^#;(#
M_P`(K\3BQZ`6-@0?_)RE/_!PG\'-@(\)_$\MW'V"PQ_Z65\@?`G_`(+0?`O]
MI70GO_!G['/PXU86X7[3;+!9-=69;=M$L::>VW.QL')!VG!.#7=)_P`%"_`,
MJJR_L.>`V5SA2+*V(;Z?\2SV/Y5]=A.&<'7I1K4L#4E&6J:KTK?EWO\`D>'6
MS;%4ZCI3Q$5):->SG_EYK[UW/OW]BG_@H;X*_;N/B)?"6G>)=,E\,"W-W'K%
MO#"S"?S=A3RI9`1^Z?.2#P.*]XK\M/AK_P`%A8/A#;W$/@[]E#3O"T6IL&F3
M1KH6*W14$`L(M/7<5!/)SC)K[`_X)^?MVZG^VYHWB.YU+X=ZMX%.@S0QQO<7
M#W-M?B17)$<C0Q9="GS*`=H>,Y^;%?+9]POC,)SXI4'3HIJW-.$FKV6O*]=>
MR_(]O*\ZH5U"A*IS5'?:,DGUZKM;K^9]%T445\F>Z?SB>!?B-H?_``2O_P"#
MM'X@ZY\;[BS@\.^--3U6\TWQ1JT<HM]%@UB(W-G<Q2.GW(]QT]Y%_=Q@S@L%
MC;'ZV?\`!2K_`(*U?L[_``#_`&'?'NMZCX]^&?Q!76/#MU:Z=X6LO$%EJ$WB
MG[1']G6%($D9I8&:91*R@A(B['.,'K?^"F/_``2`^#'_``5:\$Z?IOQ,TO4K
M36=%;.E^)-$GCM=7TY"P+PK))'(CPOCF.1'4$EE"O\P^)/A-_P`&9?[.?@GQ
M*VH>(_&_Q/\`&$$6_P`BPFN;2SM261E4R^5#YC[6*N`KH"4`8,I*D`^.O^#;
M3XAZOH/_``2(_P""@T-K>W,,?A_P;<:M8A)67[-<OHNJAI4Q]UC]FAY'/R+Z
M"NX_X,]O^"@_P;^`OPR^)_PL\=:_X0\!>,-9UR'7].U;6;R&P_X2"V-ND'V,
M3R;5+6[QLZQL^YOMLA13MD(^S](_X(R>`/\`@D!_P2N_;)M/`GB?QCXE3Q]\
M,]9EO3KTELYMS:Z1J(01^3%'C/VA\[L]%QCG/YF?\$`?^"$OP@_X*Y?L4>,]
M?\<:KXQ\,^*?"WC*73K/4]`NX4\^W:RM)!%/%-%(K*CF1E*;&S(V688``/JC
M_@[J_P""C_P=\?\`[&_AOX.^%/$GA+X@^,]7\3Q:O,VD:E;:BOA>*TB<-)*T
M4C-#<2_:5C12OS1M<$D84-\R?\%W/A+XU_9/_P""'?[#/PK\976HC6;9-0U+
M5K.Z9EEL9S%'-%:2*>CVL=\]OC^'RR!Q7Z8?L$?\&K?[.?[$GQ;TKQYJ-UXG
M^*?B71&,MA%XF^ROI-G/R%G6T2(!Y%!RIE>0(P5U"NJLORS_`,'OO_)+OV=_
M^PKKG_HFQH`^_P#_`()A_P#!6K]G;XX_L'_#K5++X@_#7P!)H7ANST_4_#&H
M:_9:=-X9>VB%NT)ADD5DMP86\IR`'C"L,<@?D[\5_B+H/_!57_@[+^&NJ_!"
M33+G0/`FJZ1<ZIXHTI9&MM=AT;_3+R[DE1.5<*-/CD),<@2W`<I(M?2F@_\`
M!H'^SW^T%\./!?C72O&7Q+\%2>)M#T[4[_2[.YM;NRCDEM(FD$'G0F6,,Y9L
M/)(`6(`"@*/T#_X)F_\`!'[X+_\`!*3P9J.G_#/2M1O-;ULXU3Q+KDT=UK&H
M1AMRPM(D<:)$IQB.)$4[0S!F^8@'Y"_%O_E=VM/^PUI7_J(6U)_P=J_\I:?V
M:_\`L"6'_IYFK]1O$W_!#3X<^*/^"L47[7DWBSQK'XZANK:[&CH]K_9):'3$
MTY1CR?-P8HPQ_>?>/IQ1_P`%(O\`@AE\./\`@II^TCX#^)OC#Q9XWT+6/`%K
M#:6=KH\EJMM<+'=-<@R"6%VR68@[6''OS0!^4'_!Z=\#=?T?]LCX._$^<S)X
M/UOPI_PC,=Q;JTDEG>6=]<7,I8?*BEXKZ(QC>"YAEZ!,TW2?^"9*Z]\)(_'-
MI_P5IT0^&I+=;G[5/XANK=HPRAA&\3ZH)8YL$#R602!CM*AN*_?+]J_]DCX>
M?MO?!/4_A[\3_#-CXI\+:J5=[:?<DEO*N=D\,JD/%*N3AT(8!F&<,0?RT/\`
MP95?L^_\)091\4OC(-#/_+IY^F_:NG_/?[)L_P#(5`'D'_!N%^QI\)_BM=?M
M,:_\,_C5\0_'OQ-\1>"KKPI>>)+_`,./H=MHO]K,\BW&Y[B>:XNGGM%E$F5V
MB)\@EP:X7_@T=_;4^&G[%GCKXX?"KXO:OHGPL\9:Y?V$EK-XF<:2]Q+9FZAN
M+">2?8L4T,D@VQ2$.6FF`&5(K]U/V,/V)/AI_P`$_P#X&V'P\^%?AJU\.>'K
M.1KB8K^\N]2N'QON;F9OGFF8!5W,3M5$10J(BK\K?\%,/^#;_P"`'_!3+XI/
MX^UE_$W@+QW<P^5?:IX9FMXH]9(VA)+N&6)UDD15*AT,;D$!V<*@4`^8?^#K
MW_@IE\$]:_8!G^#>@>(O"/Q"\=^--6M)X$T?4K746\*I9SQ3R74QC9S!)(A\
MA%.UG2>8@E58%WC3]BSQE^S;_P`&\G[.OAW6M.N[34/!DPUGQ#831/!+I)U2
M6ZN52>.0*R2Q2WL<#H5RLCL.@)KV']AO_@U$_9O_`&/?BGIOC36[GQ-\6=:T
MG<UK9^*%M)-&BD(($ILTA'F.H)V^:[J&PP4,JD?I?XA\/:?XNT*\TO5;&SU/
M3-1A:WNK2ZA6:"YB889'1@592"000017JY'FCR['TL<H\W)).W==5\T<.9X)
M8O"SP[=N9;^>Z_$^9O\`@G?^VM\,/%_['W@2T;Q9X<\/ZEX<T6UTB_TO4=1@
MM;BTEMXEA)"/(6,3F,LC$DLI&<,&4?'WQM\::+^VW_P6N^')^']W97]AX;N=
M-^TZI&P>UO\`[!/)?SRHZ`[EV?N58\,Z*`=I5C[GXY_X-^/A5KWB"6[T3Q)X
MR\/V<SEOL(GANHH!V6-I(_,QU/SLQ]Z^@_V//^">WPW_`&)+*Z;PC87=YK-\
MABN=:U1TGU"6(L&\D.J(J1Y5?E15#%%+;B`:^N68Y%@'6QN7SJ3JU(SC&,HI
M*'.K-MI^]9-VMUW/G_J>98E4\-B81C"#BVT[N7+V72_R/BC_`(*@(LO_``66
M^!"LH96'AL$$9!']N7'%?4G_``6>_P"4;WQ!_P"NFE_^G2TKHOC[_P`$ZO"7
M[0W[47@_XKZMK/B*SUSP9]@^R6EI)"MI-]DNWNH_,#1LYR\A!PPX`Q@\UZ!^
MU)^SGI/[5_P+UGP#KE]J6GZ7K9MS-<6+(+A/)N(YUVEU9>6B4'*G@GOS7G3S
MK#.>6R3=J"7/IM:HY:=]&=<<NKJ&,5OXE^77>\;?+7N?GW;>%;[Q5_P;HVPL
M(;^YETZ:>^EAM59R\,>ORM*SJH.8XTW2L>BB/<2`#7LG_!'']K'X<P?L6>&?
M!U[XJ\.Z'XC\,O>QWEC?7R6LK^9=S3+,@E8%U*3)EERH8L.,`5]/?LP?LX:-
M^RK\"-&^'NC7FH:GI.C?:#'-J!C:>837$D[AMBJI`:4CA1QC.:^7_C#_`,$$
MOA+\1_&FH:SHVK>)_"*:G<&=].L6MY+"UR!N6"-X]T:ELG;O*KG"A5`4=LLZ
MRS&TL3@L;*4(2K2JPFE?>ZM);ZJUM=&<T<NQN&G1Q6'BI25-0E%NVUMGMN?*
MG_!=3]J/P'^T+\2_!^D>"]4L_$$GA*TNCJ&JV$D<]E.;@6[QQ1S*2)2@C8MM
MRJF3&=P=5^BO^"U'_!,O]GC_`(*D^*O!?@SX@?$[3/AK\8M)LIYO"KPZA91Z
MCJ-K,X#H]I,5DO(%>%B%C93&Y8A@'8/M:G_P;]_!V\T"PLX==\=6US;-*UQ?
M"]MWFO-^W:K*8?+54PVW8JD[SN+<89_P5Q_X(&_#C_@KMXQT#Q1XJ\9>-_"?
MB;PQI1TBPDTIK:6Q,1E:4M+!)$7=MSGE94&,<'K7'Q/F&65<'@\'ELI25%33
M<E9N\D[]M7=I7=E9,ZLEPF,IXBOB,7%)U.6UG=:)Z?+1>;/R2^&^L_M*?\&]
M_P#P5@^"_P`&KSXTCXK>!_%VI:?92>%++5;N^M1IU]=BT93ILKC['>C<983&
M2K,L>6D4R1UV?_!3;QE;?\$T?^#K/P[^T#\6O#6HW'PK\1?8]3TZ]@LQ=)*B
M:!'I,DR!AM:6TNPLS1J3(JB)@,O'G[R_X)Q_\&MWP4_8(^/FB?%'5/$WBGXH
M^-/#4C7&E?VS#;PZ98W&,)="V569IX^L;/*P1L.JAT1E^P?V^_\`@G'\)?\`
M@I7\'9/!OQ4\-0:I#"K_`-F:M;JD6KZ#(Y0M)9W!5C$6,<>Y<%)`BAU8#%?&
M'T1N_"?]O+X'?'C7K'2?!'QC^%GB_5M3W?9+#1O%5C?7=P51G8+%'*SDJBLQ
M&,@*Q.,&OQ@_YWH/\_\`1/Z^ROV&?^#7;X)?\$__`-KOPC\8?!WCGXJ:GK'@
MV2ZDM+'6;NPFMIO/M)K9A(8K6-CA)F(P1R!VR*]C_P"'*GP^_P"'N?\`PV-_
MPE/C+_A/?^@-YEM_9'_(%_LCIY7G?ZGY_P#6??\`]GY:`/P?_P""R?P@U/P-
M_P`'(7C*V\5?$[Q%\&--\9ZA::AIGQ">TN5%A:7.EQQ)+$T;Q.]LDPDLGEC?
M:@BESGRV6O3?VHO^"<ME\!?V?]1\5^+/^"I5IXD\.7=MY1TS1]4N-:NM;BE9
M8FCM[6/56:Y7]Z-X`*JA9F(4$U^YO_!2;_@E3\(/^"J?PJL_#'Q1TF]6ZT>7
MSM(U_2)8[;6=&+,IE6"9XY%V2!`KQR(Z-A6VAT1E^"_AI_P9?_LZ^%O&D>H>
M(O'OQ5\5:5;RI)'I9NK.RCG`(+1S21P>8R-R/W9B8`\,#S0!P7[#?[.WPM^!
MO_!LA^TWK?PJ\0^-_%UGXST#7I=0\0Z_H+Z$FJRP69@Q96Q=_P#18_GB+^9(
M6F2X!8;1&GI__!F%&L?_``2O\9LH`+_$_46;W/\`9>E#^0%?HK\7/V*?`WQ*
M_8Q\2_`C2]-M_`_@/Q#H%SX=2U\.VL-FNF6\ZLKF"/88U;+,W*D%B20237$_
M\$M_^"8_@[_@E!^SSJGPW\#Z[XF\0Z1JNOS^(9+G7)('N4FE@MX"@,,<:[`M
MLA&5SEFYQ@``_)F&!+?_`(/G2L:)&I8L0H`!)\`$D_4DDGW->9Z5\3M%_P""
M5?\`P=H^.?$WQMF@C\->*M6U*]L?$M_!,T.D6VL6QEM+F)F3)2+S/L,CK\D8
M%P-VV,BOU[_X<J?#[_A[G_PV-_PE/C+_`(3W_H#>9;?V1_R!?[(Z>5YW^I^?
M_6??_P!GY:Z[_@I5_P`$C/@O_P`%5O`NGZ3\4-'OX=5T5LZ5XCT6=+36-,4L
M"\<<KI(C1OC!CE1TR=P`8!@`>E_##]MOX+_'/Q!::-X)^+_PP\7:OJ(<VMGH
M?BFPU"YN`B%W,<<4K,VU%9C@'`4D\"OY,_\`@F;^S5J>M?M+>-/A1XM_:1U;
M]C[Q39MY$YU1I].M-2NK9Y$DL[F5;JW6*>,N3&LF0^^0*0VU9/WV_8!_X-B/
M@S_P3J_:Z\+_`!A\'>.?B=J^M^%%O%MK+6;FQEM91<VDUJV_RK:-LA)F(PPY
M`[9![K_@IY_P;S_`3_@J/\08?&WB9/$/@OQXL(@N]=\,2V\$NLJJ)'$+U)8I
M%F,:($5QLDVA5+E415`/Q6_;^_89\$_LZZ'IOA_XJ_\`!234/B'8Z]/^\T+0
M[&Z\5R0"(+();BW75&CB7+1[#*5+DDH"$<K^L/Q<_P""8?[(/C[_`():_`O]
MG_XB^)[OX<Z3]A.I^`-2\5ZC::'XOAN9F6ZNPJW2X$LK70\^T*'&]1L1XHVC
MS?V+?^#2[]FW]E3XH:;XP\17OBCXM:CI19H-,\3)9OH;.00'DM%A_>E<Y"R2
M,F<$J2!CZ*_X*S?\$9OAS_P5^\-^#K+QYXB\9^'+CP')>2Z5/H,]LBLUT(!*
M)EFADW@"W3`4H02<D]*`/PJ_;5^`/[1W_!K_`/%OX=:G\/OVB#XD\'>);RYO
M=*T.&[N;>TOE@\LRKJ&D-(T#Q2"XVB1'9MVY@T3A&K^HK2[XZGIEM<F">V-Q
M$LODSKMEBW`':PYPPS@C/6OR2_92_P"#/3X%?!#XLZ1XK\=^-?&'Q7CT*Z2[
MMM#O[:VL])NRF2L=W$!(\\8;:WEB1%;;APZ,R']=*`/S>_X+;_\`!NWX%_X*
MG1W7COPM=VG@/XW6]H((]6,873?$>P1K&FIJD;2LR11^7'/'\Z*0&654C1?Y
MUOBK\#OVH?\`@B)^T67OH_'/PE\2PS/;6.O:7-+%INO1IY<C""Y3]S=PD-&7
MC.X#<%D16!4?VE5S/Q>^"W@[]H'P+=>%_'?A7P[XS\-WS(\^EZWIT-_9RLC!
MD8Q2JREE8`J<9!`(P:`/YR?@[_P>/_&^TL[:R\:^%?A[=21HJ'4;'1I1)*1P
M7DC-RJY/!.S`ZX7H*^W?V9?^"UOQ]_;'@@/PPTOX/^-+J>%I_P"S]/DB.I1(
MK,I:2T:^%Q$,J?OQKD<C@@UR?[>G_!FI\-OB3;:GK?[/_C'4OA[K\[F:'0/$
M$K:AH)^50(HYE4W5NN0S%G-SRV`H&`/R5_:J_P""$'[77[`GCA+FX^&_BGQ!
M;6#&>U\3^`X[C5[--BJQE\R!!/;;2V,SQQ$D'&0,U[N79U##1Y:F&IU/.4=?
MP:3^:OYGDXS*I5I<\*TX>2EI]SV^6GD?OM!^T[^WC(8@OP7\*_,"039<?B3?
M?SH'[47[>,1"'X+>%CM)!_XE^[]?MO-?SN_#[_@MK^U;\.%6V;XZ_%'6;2(L
M#;:MXFO[@Y.1S)YPE&/3?CVKW_X+_P#!??XA^);^UT_Q?\4_BCX7,\JQMJ,?
MBG4[FR@4]9)$C=IE`XX1)">?I7T66YAEN)LJM.C3?]Z,[??&^]OQ^[Q,9E^,
MH_PZE6?I)?D['[3M^U!^W?!A9/@KX6+'GY+$,/S%[7P9_P`%'O\`@D!\;/\`
M@HGK;^*;K]GO0/`?C=/,DGU;PQ8P:>=9D<@@WL?VAEF;.?W@42?-RS``5[9^
MS/X/^,/[9-O"WPN_;4\$>-KJ:#[4=/T[XJZPVI0Q9(W2V;1"XA&0?]9&I[].
M:^(O^"BO_!5KXE_LA^*9O!_A#]I;4/B7XI$:FYU+PIXYU/4])TLE0=K7#%(Y
MI@I`VQ%U0DAR&0QGU,94RF.&DE+#2LOLQJ*3]'9:_-')1I8]U%;VR]91M\_+
MY'P;^R;^UE\5/^"3?[9/_"4>%+D:-XQ\&7USH^LZ7=.9;'4%1VAN+*[CC<+-
M'O4G&?E>-)%(9$8?TIV?[4G[=VH6\#P_!KPF\4B"1&^QC:P(Z@F^YS_+FOYT
M/^"7'_!+WXF_\%9?VCI/"_@^T<Z7IJ_;_$_B._=X[#2(FWE!-.$D/GSLC)&@
M5W8[WV[(Y63^@I/^"8/[9UJ@"?'[/;Y?'NNC_P!H"OF>&(X3]Y];E26UO:*;
M[[<J?SO^A[>>*NW#V*J/>_(TNV]_P.C3]J3]O!54?\*5\+X[_P#$N)/_`*6U
M-%^U;^WA&@`^"_AM2>NW3\#_`-+:Y?\`X=F?MH_]%]D_\+_7/_C-'_#LS]M'
M_HOLG_A?ZY_\9KZVE_9$'?VF%?K&J^W]W^KGSSIYAVK_`/@43Z#_`&+?C=^U
M?\1OC-%9?%7X=>%O#/@J.VEDN[Y8VM[E9-I\I(0+B7>2^-P90H4,=P;:K?7]
M?EY_P[+_`&T<D_\`"_'R?^I_US_XS6IX*_X)O_MFZ-XPTN[G_:#^S6]O=1O-
M*_BW5M2$:;OF;[--"(IB!DB-R%8C!(!R/G\TRC+J\W6I8NA#3X8JHE^,7J>Q
M@<?C*%-4YT*D_.3C<_2^BBBOA3ZH\I_;P^%6M?';]AWXS>!_#=O%=>(O&7@7
M6]#TN&2584FNKK3YX(49V(509'4%B0!G)KXR_P"#9G_@G'\5_P#@FK^R=X]\
M*_%O1;#0];U[Q:VJV<-KJ4%\LEO]CMXMQ:)F4'?&W!.>*_2.B@`K\L/^#GS_
M`():_&/_`(*<>`O@_8_"'0].URZ\'ZAJD^I)=ZI;V`B2>.V6,@RLN[)B;@9Q
M7ZGT4`<=^SOX0O\`X??L_P#@70-4B6#4]#\/6&GW<:N'6.:*VCC=0PX(#*1D
M<&NQHHH`****`"BBB@`HHHH`*\_^,_Q=F^&GC'X>V$<$TT'BK79=.NC'937+
MK$FFWMR"GE@X8R01CY@?E+\<;E]`KB?B_P"&Y-0U?P=K8\XVWA'69-4NXX8G
MFEGB;3[RUVK&@)<AKE6VXR=O&2`#I24>;WE=:^733\2*CDH^[N9Z_'SP]X5U
M;QTNJZC>+!X5N89M2E%G<3P:7%);0N`[HK*NU3YCC(,:.LCA48.W5:Q\1-+T
M3Q-8Z-*U[-J6H))+'%;64UP$1.K2,BE8@3PID*[B"%R014?A;2&TZ_\`$\S0
MB$7^H"97*%3*HM8$W$XRW*$9YZ8[8KS#5]-OOA;XRUSQ#JE]XGBTG7K:P\N7
M0]*;5;R-XH?*>U>".VFF$2D&59%)0M<S`JA`:7HC3IS;MT2Z[O3;3U[O\SFJ
M5*L;**O=OILM?/TZKOY'K7@_QG8>.M(-[I[7'EK(\+QW%M+:SQ.IP5>*55=#
MT(W*,@@C(()GM?$MC>^([W2(I]VHZ?!#<W$6QAY<<S2+&VXC!R89.`21MYQD
M9X_X/^$[NP\2>(]?N9+YXM=-JMLUX/*N+B.*(XFFA$40BE+2&/:4+[(8RS](
MX\G7/%`^$OQWU_6=6L-:FT;Q'INE6-C/IFE7>J.;J*2_,R2);12-"BI)`1))
MM4F0C/%92H^\XQZ?\#TVZZ=#2%9\L925KNWYV[[^O4AU[XGBX_:$\&3V-[J,
M^A77A;Q!++;V\4TBS30W^CPJ[0J,LT9DE4-M)4.^#AB3U>D>.CXDUC03!>O:
M1W,,YGL[C2YXYKIE2,[HW?:%5"XZJV_<,$;37`?#7P3KME\1/AE>ZGH]SITT
M7@S7AJ,3,DRZ7=W=[I$XM7E0E&==LR@J2&\ER.*Z3PIJ5WXH\0^#;JXT?5M,
MN-.TVX@U&WNH2/L,[PVC^5YJYBDP25$D;LC,CA6)4XUG"FXI)[)_^W?\`SE6
MFN5VWM=6>[<?R3>GZ(GL?VJ/`VJ7.@16VKRW#>*_-.AF.QN&765C<*[VYV8E
M0*?-#(2IAS,"8@7K8_X71H#^!D\1)+J$NG/</:!$TRZ:\:9)7B>,6PC\\NKH
MX*A,@*S?=!-<#X,\$:A;>`/V>X+C2KI+CP]]G-^CVY#Z>1H%Y`QD&/D_>.L9
MSCYG`ZG%=)X]T#4-.^)&@^+(X)K_`$S0%OXKRQ1&:1!/'#MO8D56:66+RGB"
M*`QCNYRI)`CDF<*/-RQOUUNO/R6^@J=2NX.32OI;1Z72OUUM=]NQT-I\5-)O
M=9U73%_M&/4='@2YG@DT^=&DC8'#Q90"<#&#Y1;:<`X)Q7$_`G]INS\:_L]?
M#WQ/XB,EEK'B[2=.E:W@T^YQ=7MQ:K.\=M'M9Y5`$C97<%2-F9MJLPIZMXXN
M_B5\7OAIJ^@:!JXT6UU"_MM1U*_TR[TR[A1["X*P?9[B%)/(>2.-GD?:OF1V
MX42$G9Q_PM\(:S\+/AW\,K"_T_Q!;3_#;PJ?"^MWFDZ<+JYMV6WM"LELA@D:
MZMI39\BW+2J[P!H^'\K2-&G:SNF_-7^UIMULNE]?-$NK7YF[:*ZVW^&SU?2[
MZVT9[UX9^(^D>+=?U;2;.XF&J:&8_MMI<6TMO-$L@)CD"R*I>-]KA9$RA:.1
M0VY&`=XL^(.E>";O3+;4)YEN=8N/LMG#!;2W$LS[68X2-6;:%5B6(PH')%<'
M\,--;QM\2K+Q1#+XLN-,TW1Y[*UN-<T_^S6F:>XB,D:VS+#,AC^QH2T\&")D
M\IR#*#<\8>&[^^_:U\#:G%9W3Z99^$?$5I<7:QDPP2S7>BM%&S=`SK#*5!ZB
M)_0UG.E!3Y;VT;]'9Z?/3II>VZ-H5IN',XZWM^-K]=O4UM0_:"\*Z;H.H:M+
M?W!T?2;MK*\U%+*>2SMY%?9(6F5"@CB?<LDF?+B*.'9-C[=34_B=I&E>,;70
M&ENKC5KJW:Z$%K9S7(AB!(#RO&I2(,0P3S"N\HX7<4;'CWA'Q#?^`O".F>%!
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M7P7KL:NEIX+\27>L7D*PR33SP/I]_:`1(BEF;?=1M@`DJK8R<5FJ5.,[2U5N
M_>-[775.R]=RW.;7,M/EV>^^S6N^QVOA_P`:Z;XIU+6;*QN&FNO#]VECJ$9B
M=#;3/;PW*IE@`W[FXB;*DCYL9R"`G@/QOIGQ,\#Z-XDT2Y-YHVOV4.HV$YC:
M,SP31B2-]K`,N58'#`$9P0#D5YOHWB(?!7XN^,O[6TWQ#=6_C_6+74]*N].T
MBYO[<D:?96+PS/"C"W97M0Y>81QE)U*NVR4):_89;SOV*/A`3AE;P5HX]L?8
M8145*"C3]HO[MOFFW]ST\NIJJMZBAY-_<TCI;GXL:3KMSJ^E:;)J%S=62212
M7$6GW!M%D5&+*MSL$+,I4JP5R58;3AOEJ/PC\=_#'BT>'H[+4'9/$\4LFDS2
MVTT,.I")=Q$4CH%<LF9$`.9(T>1`R(S#E?@VUW\*?@WX9^'>LVFKW&O:5I!T
MB.[BL;BY@U!;:)HUNY)T5XX6G2,2^7))N#2;,LW)[;QAHIO]6\'NMKYILM4,
MQ<1Y^SC[#<IOSCY?O!<_[6.^*=2-*-X[V;LTUVTZ;/\`SZF-.=5OG?6VEGWV
MWW773[D5M3^._AO2M/UF\DGU&6QT"X^RWUU;Z9<SP1.&"OB1(RKK&Q(D="RQ
M%)`Y0QN%O>,?BEH_@C4--L[U]1>[U??]FBLM-N+V1E0`LY$,;[$7<H+OA064
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M6Y$94QR,Q3<'7=L`!^I_[;W_``3+_97_`&DO!WB'7?C-\-/AM%%+$L^J^*[B
M&'1M0@2,KM>34XS',BC"CYI=I'RG()!_E_\`^"I_[+G['_[/GB2_3]GG]H/Q
M7\3KL7+6ZZ')X9\^TL"CJ)&DU@O;Q31LI<QFVMI@=F&<`AZX*VA_:D_X+.?'
M)8D/Q*^.7BV-PN6>2YM-&65B1DDBVL8696ZF*/(/I7Z#_L0_\&:?Q>^+.G1:
MO\<?&>D?".V\U"-#TZ.+7M6EC$CB19)8IA:P%D561TDN/]9\R*5*D`_&JQO;
MBPN!+;3302A6&^)BK`$$,,CL02#[$U^I7_!+;_@U:^-7[:.H6?B3XMV^J?!/
MX<R(ES&^H6B-K^LKYI5HH;-V#VORHW[VY5<;XV2.92<?O7^P-_P1&_9O_P""
M;][!JWP[\`6LWB^*!(6\4ZY,VIZPQ574NDDG[NV9Q(X?[+'"KC`92%&/K*@#
MS;]E#]D+X<?L/_!O3_`7PN\*Z9X3\-6'SF&U3,MY*5"M/<2MEYIF"J#)(68A
M0,X``])HHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`\_P#$OPO\4KXE
MUB^\,>+[71(M?:.2ZAO=);4#;R*B1-);GSXQ&S1(HPZR('4/MY=7Z[P7X0T[
MX>^#])T#1[5++2=$LX;"RMT)*P0Q($1`222`J@<DGBBBK<VURD1IQ3YEO_7W
M&E1114%A1110`4444`-$A.<#H,T"0G&0!GWHHJ[:$.3YK#J\1_:,_P"";7P&
M_:Z^*_ASQQ\3?A3X.\<>*/"L#VMA>:M8BX!@8L?)GC/[NYB5F=D2=9%1G=E"
MLS$E%06>QZ!H%AX4T2TTS2[&STW3;")8+:TM85A@MXU&%1$4!54`8````JW1
D10`4444`%%%%`!3/.XR1@9Q110`OF':&`!!QWYYIU%%`'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
